• Home
  • News & Events
    • News Releases
    • Events & Presentations
    • Publications
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Governance Documents
    • Committee Composition
  • Financial Information
    • SEC Filings
    • Annual Report and Proxy
    • Special Meeting Proxy
  • Stock Information
  • Resources
    • Email Alerts
    • Contact

Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Oct 3, 2024 | Press Releases

CINCINATTI, Oh., Oct. 03, 2024 — Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or “the Company”) (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of...

Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Oct 3, 2024 | Press Releases

CINCINATTI, Oh., Oct. 03, 2024 — Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or “the Company”) (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of...

Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders

Sep 20, 2024 | Press Releases

CINCINNATI, Ohio, Sept. 20, 2024 — Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s...

Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders

Sep 20, 2024 | Press Releases

CINCINNATI, Ohio, Sept. 20, 2024 — Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s...

Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds

Jul 15, 2024 | Press Releases

CINCINNATI, July 15, 2024 — Onconetix, Inc. (“Onconetix” or the “Company”) (Nasdaq: ONCO), today announced the closing of the previously announced exercise of certain existing warrants to purchase 7,458,642 shares of its common stock...

Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds

Jul 15, 2024 | Press Releases

CINCINNATI, July 15, 2024 — Onconetix, Inc. (“Onconetix” or the “Company”) (Nasdaq: ONCO), today announced the closing of the previously announced exercise of certain existing warrants to purchase 7,458,642 shares of its common stock...
« Older Entries
Next Entries »

Recent Posts

  • Onconetix Acquisition Target Realbotix Launches Echo Humanoid Robot Line with Tabletop and Full Body Models Designed for Education, Wellness, and Social Engagement
  • Onconetix Announces Reverse Stock Split
  • Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition
  • CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
  • Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition

Recent Comments

No comments to show.

Stay up to date

Keep informed on investor news & updates

© 2026 Onconetix